NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.3 Sex hormones and hormone antagonists in malignant disease > 8.3.4 Hormone antagonists > 8.3.4.2 Gonadorelin analogues and gonadotrophin-releasing hormone antagonists > Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA377

Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - NICE TAG TA377

1.1 Enzalutamide is recommended, within its marketing authorisation, as an option for treating metastatic hormone‑relapsed prostate cancer:

  • in people who have no or mild symptoms after androgen deprivation therapy has failed, and before chemotherapy is indicated

  • and only when the company provides it with the discount agreed in the patient access scheme.

 https://www.nice.org.uk/guidance/ta377

Site by Devopa
© Copyright 2020 NHS. All rights reserved.